Skip to main content
Top
Published in: Inflammation 3/2016

01-06-2016 | ORIGINAL ARTICLE

IFN-τ Alleviates Lipopolysaccharide-Induced Inflammation by Suppressing NF-κB and MAPKs Pathway Activation in Mice

Authors: Haichong Wu, Gan Zhao, Kangfeng Jiang, Xiuying Chen, Guangze Rui, Changwei Qiu, Mengyao Guo, Ganzhen Deng

Published in: Inflammation | Issue 3/2016

Login to get access

Abstract

IFN-τ, which is a type I interferon with low cytotoxicity, is defined as a pregnancy recognition signal in ruminants. Type I interferons have been used as anti-inflammatory agents, but their side effects limit their clinical application. The present study aimed to determine the anti-inflammatory effects of IFN-τ in a lipopolysaccharide-stimulated acute lung injury (ALI) model and in RAW264.7 cells and to confirm the mechanism of action involved. The methods used included histopathology, measuring the lung wet/dry ratio, determining the myeloperoxidase activity, ELISA, qPCR, and western blot. The results revealed that IFN-τ greatly ameliorated the infiltration of inflammatory cells and the expression of TNF-α, IL-1β, and IL-6. Further analysis revealed that IFN-τ down-regulated the expression of TLR-2 and TLR-4 mRNA and the activity of the NF-κB and MAPK pathways both in a lipopolysaccharide-induced ALI model and in RAW264.7 cells. The results demonstrated that IFN-τ suppressed the levels of pro-inflammatory cytokines by inhibiting the phosphorylation of the NF-κB and MAPK pathways. Thus, IFN-τ may be an optimal target for the treatment of inflammatory diseases.
Literature
1.
go back to reference Saugandhika, S., V. Sharma, H. Malik, et al. 2015. Expression and purification of buffalo interferon-tau and efficacy of recombinant buffalo interferon-tau for in vitro embryo development. Cytokine 75: 186–196.CrossRefPubMed Saugandhika, S., V. Sharma, H. Malik, et al. 2015. Expression and purification of buffalo interferon-tau and efficacy of recombinant buffalo interferon-tau for in vitro embryo development. Cytokine 75: 186–196.CrossRefPubMed
2.
go back to reference Chethan, S.G., S.K. Singh, J. Nongsiej, et al. 2014. IFN-tau acts in a dose-dependent manner on prostaglandin production by buffalo endometrial stromal cells cultured in vitro. Reproduction in Domestic Animals 49: 403–408.CrossRefPubMed Chethan, S.G., S.K. Singh, J. Nongsiej, et al. 2014. IFN-tau acts in a dose-dependent manner on prostaglandin production by buffalo endometrial stromal cells cultured in vitro. Reproduction in Domestic Animals 49: 403–408.CrossRefPubMed
3.
go back to reference LeMessurier, K.S., H. Hacker, L. Chi, E. Tuomanen, and V. Redecke. 2013. Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathogens 9, e1003727.CrossRefPubMedPubMedCentral LeMessurier, K.S., H. Hacker, L. Chi, E. Tuomanen, and V. Redecke. 2013. Type I interferon protects against pneumococcal invasive disease by inhibiting bacterial transmigration across the lung. PLoS Pathogens 9, e1003727.CrossRefPubMedPubMedCentral
4.
go back to reference Gough, D.J., N.L. Messina, C.J.P. Clarke, R.W. Johnstone, and D.E. Levy. 2012. Constitutive Type I interferon modulates homeostatic balance through tonic signaling. Immunity 36: 166–174.CrossRefPubMedPubMedCentral Gough, D.J., N.L. Messina, C.J.P. Clarke, R.W. Johnstone, and D.E. Levy. 2012. Constitutive Type I interferon modulates homeostatic balance through tonic signaling. Immunity 36: 166–174.CrossRefPubMedPubMedCentral
5.
go back to reference Cho, H., and B.L. Kelsall. 2014. The role of type I interferons in intestinal infection, homeostasis, and inflammation. Immunology Reviews 260: 145–167.CrossRef Cho, H., and B.L. Kelsall. 2014. The role of type I interferons in intestinal infection, homeostasis, and inflammation. Immunology Reviews 260: 145–167.CrossRef
6.
go back to reference Bartol, F.F., R.M. Roberts, F.W. Bazer, G.S. Lewis, J.D. Godkin, and W.W. Thatcher. 1985. Characterization of proteins produced in vitro by periattachment bovine conceptuses. Biology of Reproduction 32: 681–693.CrossRefPubMed Bartol, F.F., R.M. Roberts, F.W. Bazer, G.S. Lewis, J.D. Godkin, and W.W. Thatcher. 1985. Characterization of proteins produced in vitro by periattachment bovine conceptuses. Biology of Reproduction 32: 681–693.CrossRefPubMed
7.
go back to reference Alexenko, A.P., A.D. Ealy, and R.M. Roberts. 1999. The cross-species antiviral activities of different IFN-tau subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential. Journal of Interferon & Cytokine Research 19: 1335–1341.CrossRef Alexenko, A.P., A.D. Ealy, and R.M. Roberts. 1999. The cross-species antiviral activities of different IFN-tau subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential. Journal of Interferon & Cytokine Research 19: 1335–1341.CrossRef
8.
go back to reference Bazer, F.W., J. Kim, G. Song, H. Ka, C.D. Tekwe, and G. Wu. 2012. Select nutrients, progesterone, and interferon tau affect conceptus metabolism and development. Annals of the New York Academy of Sciences 1271: 88–96.CrossRefPubMedPubMedCentral Bazer, F.W., J. Kim, G. Song, H. Ka, C.D. Tekwe, and G. Wu. 2012. Select nutrients, progesterone, and interferon tau affect conceptus metabolism and development. Annals of the New York Academy of Sciences 1271: 88–96.CrossRefPubMedPubMedCentral
9.
go back to reference Ying, W., S. Kanameni, C.A. Chang, V. Nair, S. Safe, F.W. Bazer, and B.Y. Zhou. 2014. Interferon tau alleviates obesity-induced adipose tissue inflammation and insulin resistance by regulating macrophage polarization. PloS One 9: 1–17. Ying, W., S. Kanameni, C.A. Chang, V. Nair, S. Safe, F.W. Bazer, and B.Y. Zhou. 2014. Interferon tau alleviates obesity-induced adipose tissue inflammation and insulin resistance by regulating macrophage polarization. PloS One 9: 1–17.
10.
go back to reference Hara, K., K. Shirasuna, F. Usui, et al. 2014. Interferon-tau attenuates uptake of nanoparticles and secretion of interleukin-1beta in macrophages. PloS One 9, e113974.CrossRefPubMedPubMedCentral Hara, K., K. Shirasuna, F. Usui, et al. 2014. Interferon-tau attenuates uptake of nanoparticles and secretion of interleukin-1beta in macrophages. PloS One 9, e113974.CrossRefPubMedPubMedCentral
11.
go back to reference Zhang, S.Y., L.T. Xu, A.X. Li, and S.M. Wang. 2015. Effects of ergosterol, isolated from scleroderma polyrhizum pers., on lipopolysaccharide-induced inflammatory responses in acute lung injury. Inflammation 38: 1979–1985.CrossRefPubMed Zhang, S.Y., L.T. Xu, A.X. Li, and S.M. Wang. 2015. Effects of ergosterol, isolated from scleroderma polyrhizum pers., on lipopolysaccharide-induced inflammatory responses in acute lung injury. Inflammation 38: 1979–1985.CrossRefPubMed
12.
go back to reference Conti, G., S. Tambalo, G. Villetti, et al. 2010. Evaluation of lung inflammation induced by intratracheal administration of LPS in mice: comparison between MRI and histology. Magnetic Resonance Materials in Physics 23: 93–101.CrossRef Conti, G., S. Tambalo, G. Villetti, et al. 2010. Evaluation of lung inflammation induced by intratracheal administration of LPS in mice: comparison between MRI and histology. Magnetic Resonance Materials in Physics 23: 93–101.CrossRef
13.
go back to reference Wang, Y., Q. Tu, W. Yan, et al. 2015. CXC195 suppresses proliferation and inflammatory response in LPS-induced human hepatocellular carcinoma cells via regulating TLR4-MyD88-TAK1-mediated NF-kappaB and MAPK pathway. Biochemical and Biophysical Research Communications 456: 373–379.CrossRefPubMed Wang, Y., Q. Tu, W. Yan, et al. 2015. CXC195 suppresses proliferation and inflammatory response in LPS-induced human hepatocellular carcinoma cells via regulating TLR4-MyD88-TAK1-mediated NF-kappaB and MAPK pathway. Biochemical and Biophysical Research Communications 456: 373–379.CrossRefPubMed
14.
go back to reference Damjanovic, D., A. Khera, M.F. Medina, et al. 2014. Type 1 interferon gene transfer enhances host defense against pulmonary Streptococcus pneumoniae infection via activating innate leukocytes. Molecular Therapy Methods & Clinical Development 1(5): 1–11. Damjanovic, D., A. Khera, M.F. Medina, et al. 2014. Type 1 interferon gene transfer enhances host defense against pulmonary Streptococcus pneumoniae infection via activating innate leukocytes. Molecular Therapy Methods & Clinical Development 1(5): 1–11.
15.
go back to reference Chon, T.W., and S. Bixler. 2010. Interferon-tau: current applications and potential in antiviral therapy. Journal of Interferon & Cytokine Research 30: 477–485.CrossRef Chon, T.W., and S. Bixler. 2010. Interferon-tau: current applications and potential in antiviral therapy. Journal of Interferon & Cytokine Research 30: 477–485.CrossRef
16.
go back to reference Soos, J.M., P.S. Subramaniam, A.C. Hobeika, J. Schiffenbauer, and H.M. Johnson. 1995. The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. Journal of Immunology 155: 2747–2753. Soos, J.M., P.S. Subramaniam, A.C. Hobeika, J. Schiffenbauer, and H.M. Johnson. 1995. The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. Journal of Immunology 155: 2747–2753.
17.
go back to reference Do-Umehara, H.C., C. Chen, D. Urich, et al. 2013. Suppression of inflammation and acute lung injury by Miz1 via repression of C/EBP-delta. Nature Immunology 14: 461–469.CrossRefPubMedPubMedCentral Do-Umehara, H.C., C. Chen, D. Urich, et al. 2013. Suppression of inflammation and acute lung injury by Miz1 via repression of C/EBP-delta. Nature Immunology 14: 461–469.CrossRefPubMedPubMedCentral
18.
go back to reference Kim, Y.J., J.H. Kim, K.J. Lee, et al. 2015. Botulinum neurotoxin type A induces TLR2-mediated inflammatory responses in macrophages. PloS One 10, e0120840.CrossRefPubMedPubMedCentral Kim, Y.J., J.H. Kim, K.J. Lee, et al. 2015. Botulinum neurotoxin type A induces TLR2-mediated inflammatory responses in macrophages. PloS One 10, e0120840.CrossRefPubMedPubMedCentral
19.
go back to reference Xu, X., P. Yin, C. Wan, et al. 2014. Punicalagin inhibits inflammation in LPS-induced RAW264.7 macrophages via the suppression of TLR4-mediated MAPKs and NF-kappaB activation. Inflammation 37: 956–965.CrossRefPubMed Xu, X., P. Yin, C. Wan, et al. 2014. Punicalagin inhibits inflammation in LPS-induced RAW264.7 macrophages via the suppression of TLR4-mediated MAPKs and NF-kappaB activation. Inflammation 37: 956–965.CrossRefPubMed
20.
go back to reference Tao, W.W., Q. Su, H.Q. Wang, et al. 2015. Platycodin D attenuates acute lung injury by suppressing apoptosis and inflammation in vivo and in vitro. International Immunopharmacology 27: 138–147.CrossRefPubMed Tao, W.W., Q. Su, H.Q. Wang, et al. 2015. Platycodin D attenuates acute lung injury by suppressing apoptosis and inflammation in vivo and in vitro. International Immunopharmacology 27: 138–147.CrossRefPubMed
21.
go back to reference Roberts, R.M., A.D. Ealy, A.P. Alexenko, C.S. Han, and T. Ezashi. 1999. Trophoblast interferons. Placenta 20: 259–264.CrossRefPubMed Roberts, R.M., A.D. Ealy, A.P. Alexenko, C.S. Han, and T. Ezashi. 1999. Trophoblast interferons. Placenta 20: 259–264.CrossRefPubMed
22.
go back to reference Roberts, R.M. 2007. Interferon-tau, a Type 1 interferon involved in maternal recognition of pregnancy. Cytokine & Growth Factor 18: 403–408.CrossRef Roberts, R.M. 2007. Interferon-tau, a Type 1 interferon involved in maternal recognition of pregnancy. Cytokine & Growth Factor 18: 403–408.CrossRef
23.
go back to reference Li, D., Y. Fu, W. Zhang, et al. 2013. Salidroside attenuates inflammatory responses by suppressing nuclear factor-kappaB and mitogen activated protein kinases activation in lipopolysaccharide-induced mastitis in mice. Inflammation Research 62: 9–15.CrossRefPubMed Li, D., Y. Fu, W. Zhang, et al. 2013. Salidroside attenuates inflammatory responses by suppressing nuclear factor-kappaB and mitogen activated protein kinases activation in lipopolysaccharide-induced mastitis in mice. Inflammation Research 62: 9–15.CrossRefPubMed
24.
go back to reference Gonzalez-Navajas, J.M., J. Lee, M. David, and E. Raz. 2012. Immunomodulatory functions of type I interferons. Nature Reviews Immunology 12: 125–135.PubMedPubMedCentral Gonzalez-Navajas, J.M., J. Lee, M. David, and E. Raz. 2012. Immunomodulatory functions of type I interferons. Nature Reviews Immunology 12: 125–135.PubMedPubMedCentral
25.
go back to reference Yan, B., S. Ye, G. Chen, M. Kuang, N. Shen, and S. Chen. 2008. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis and Rheumatism 58: 801–812.CrossRefPubMed Yan, B., S. Ye, G. Chen, M. Kuang, N. Shen, and S. Chen. 2008. Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis and Rheumatism 58: 801–812.CrossRefPubMed
26.
go back to reference Namdar, A., B. Nikbin, M. Ghabaee, A. Bayati, and M. Izad. 2010. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. Journal of Neuroimmunology 218: 120–124.CrossRefPubMed Namdar, A., B. Nikbin, M. Ghabaee, A. Bayati, and M. Izad. 2010. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study. Journal of Neuroimmunology 218: 120–124.CrossRefPubMed
27.
go back to reference Sleijfer, S., M. Bannink, A.R. VanGool, W.H.J. Kruit, and G. Stoter. 2005. Side effects of interferon-alpha therapy. Pharmacy World and Science 27: 423–431.CrossRefPubMed Sleijfer, S., M. Bannink, A.R. VanGool, W.H.J. Kruit, and G. Stoter. 2005. Side effects of interferon-alpha therapy. Pharmacy World and Science 27: 423–431.CrossRefPubMed
29.
go back to reference Chen, X., J.S. Miao, H. Wang, et al. 2015. The anti-inflammatory activities of Ainsliaea fragrans Champ. extract and its components in lipopolysaccharide-stimulated RAW264.7 macrophages through inhibition of NF-kappa B pathway. Journal of Ethnopharmacology 170: 72–80.CrossRefPubMed Chen, X., J.S. Miao, H. Wang, et al. 2015. The anti-inflammatory activities of Ainsliaea fragrans Champ. extract and its components in lipopolysaccharide-stimulated RAW264.7 macrophages through inhibition of NF-kappa B pathway. Journal of Ethnopharmacology 170: 72–80.CrossRefPubMed
31.
go back to reference Wang, J., Y.T. Liu, L. Xiao, L. Zhu, Q. Wang, and T. Yan. 2014. Anti-inflammatory effects of apigenin in lipopolysaccharide-induced inflammatory in acute lung injury by suppressing COX-2 and NF-kB pathway. Inflammation 37: 2085–2090.CrossRefPubMed Wang, J., Y.T. Liu, L. Xiao, L. Zhu, Q. Wang, and T. Yan. 2014. Anti-inflammatory effects of apigenin in lipopolysaccharide-induced inflammatory in acute lung injury by suppressing COX-2 and NF-kB pathway. Inflammation 37: 2085–2090.CrossRefPubMed
32.
go back to reference Seifart, C., A. Dempfle, A. Plagens, et al. 2005. TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 65: 93–100.CrossRefPubMed Seifart, C., A. Dempfle, A. Plagens, et al. 2005. TNF-alpha-, TNF-beta-, IL-6-, and IL-10-promoter polymorphisms in patients with chronic obstructive pulmonary disease. Tissue Antigens 65: 93–100.CrossRefPubMed
33.
go back to reference Xu, D., M. Chen, X. Ren, X. Ren, and Y. Wu. 2014. Leonurine ameliorates LPS-induced acute kidney injury via suppressing ROS-mediated NF-kappaB signaling pathway. Fitoterapia 97: 148–155.CrossRefPubMed Xu, D., M. Chen, X. Ren, X. Ren, and Y. Wu. 2014. Leonurine ameliorates LPS-induced acute kidney injury via suppressing ROS-mediated NF-kappaB signaling pathway. Fitoterapia 97: 148–155.CrossRefPubMed
34.
go back to reference Cao, W.J., W. Zhang, J.J. Liu, et al. 2011. Paeoniflorin improves survival in LPS-challenged mice through the suppression of TNF-alpha and IL-1 beta release and augmentation of IL-10 production. International Immunopharmacology 11: 172–178.CrossRefPubMed Cao, W.J., W. Zhang, J.J. Liu, et al. 2011. Paeoniflorin improves survival in LPS-challenged mice through the suppression of TNF-alpha and IL-1 beta release and augmentation of IL-10 production. International Immunopharmacology 11: 172–178.CrossRefPubMed
35.
go back to reference Hopkins, S.J. 2003. The pathophysiological role of cytokines. Legal Medicine 5(Suppl 1): S45–S57.CrossRefPubMed Hopkins, S.J. 2003. The pathophysiological role of cytokines. Legal Medicine 5(Suppl 1): S45–S57.CrossRefPubMed
36.
go back to reference Wang, G., B. Sun, Y. Gao, Q.H. Meng, and H.C. Jiang. 2007. The effect of emodin-assisted early enteral nutrition on severe acute pancreatitis and secondary hepatic injury. Mediators of Inflammation 2007: 29638.PubMedPubMedCentral Wang, G., B. Sun, Y. Gao, Q.H. Meng, and H.C. Jiang. 2007. The effect of emodin-assisted early enteral nutrition on severe acute pancreatitis and secondary hepatic injury. Mediators of Inflammation 2007: 29638.PubMedPubMedCentral
37.
go back to reference Noreen, M., and M. Arshad. 2015. Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility. Immunologic Research 62: 234–252.CrossRefPubMed Noreen, M., and M. Arshad. 2015. Association of TLR1, TLR2, TLR4, TLR6, and TIRAP polymorphisms with disease susceptibility. Immunologic Research 62: 234–252.CrossRefPubMed
38.
go back to reference Takeuchi, O., K. Hoshino, T. Kawai, et al. 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11: 443–451.CrossRefPubMed Takeuchi, O., K. Hoshino, T. Kawai, et al. 1999. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11: 443–451.CrossRefPubMed
39.
go back to reference Xiang, P., T. Chen, Y. Mou, et al. 2015. NZ suppresses TLR4/NF-kappaB signalings and NLRP3 inflammasome activation in LPS-induced RAW264.7 macrophages. Inflammation Research 64: 799–808.CrossRefPubMed Xiang, P., T. Chen, Y. Mou, et al. 2015. NZ suppresses TLR4/NF-kappaB signalings and NLRP3 inflammasome activation in LPS-induced RAW264.7 macrophages. Inflammation Research 64: 799–808.CrossRefPubMed
40.
go back to reference Yamamoto, Y., and R.B. Gaynor. 2004. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends in Biochemical Sciences 29: 72–79.CrossRefPubMed Yamamoto, Y., and R.B. Gaynor. 2004. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends in Biochemical Sciences 29: 72–79.CrossRefPubMed
41.
go back to reference Ren, J., and S.H. Chung. 2007. Anti-inflammatory effect of alpha-linolenic acid and its mode of action through the inhibition of nitric oxide production and inducible nitric oxide synthase gene expression via NF-kappaB and mitogen-activated protein kinase pathways. Journal of Agricultural and Food Chemistry 55: 5073–5080.CrossRefPubMed Ren, J., and S.H. Chung. 2007. Anti-inflammatory effect of alpha-linolenic acid and its mode of action through the inhibition of nitric oxide production and inducible nitric oxide synthase gene expression via NF-kappaB and mitogen-activated protein kinase pathways. Journal of Agricultural and Food Chemistry 55: 5073–5080.CrossRefPubMed
Metadata
Title
IFN-τ Alleviates Lipopolysaccharide-Induced Inflammation by Suppressing NF-κB and MAPKs Pathway Activation in Mice
Authors
Haichong Wu
Gan Zhao
Kangfeng Jiang
Xiuying Chen
Guangze Rui
Changwei Qiu
Mengyao Guo
Ganzhen Deng
Publication date
01-06-2016
Publisher
Springer US
Published in
Inflammation / Issue 3/2016
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-016-0348-9

Other articles of this Issue 3/2016

Inflammation 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.